United Therapeutics Corporation
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +15.9% | +6.5% | +23.8% | +18.1% | +15.1% | +17.9% | +12.0% | +16.9% | +18.6% | +2.7% | +7.0% | |
| – | +30.9% | +11.7% | +1.6% | +22.1% | +5.5% | +16.2% | +7.2% | +45.5% | +5.0% | +9.1% | -4.4% | |
| – | +109.2% | +23.0% | -31.1% | -5.1% | +10.3% | +0.0% | +21.1% | +7.4% | +25.6% | +40.5% | -8.3% | |
| – | +37.1% | +10.2% | +36.1% | -1.0% | +4.9% | +23.5% | +5.2% | +47.0% | +5.5% | +9.1% | -52.3% | |
| – | +18.8% | +11.2% | +38.5% | -40.9% | -13.8% | +4.0% | +26.2% | +10.9% | +26.5% | +0.1% | +25.4% | |
| – | +21.5% | +22.9% | +7.9% | -6.4% | -7.5% | -7.4% | +8.4% | +8.7% | +9.6% | +41.2% | +16.0% | |
| – | +3.6% | -1.3% | +11.5% | +28.2% | +5.5% | -0.9% | +6.7% | +10.3% | – | – | – | |
| – | +0.0% | +0.4% | +33.0% | +129.9% | -11.1% | +0.0% | +0.0% | +0.0% | +20.4% | -4.2% | +0.0% | |
| – | -5.7% | +29.7% | +35.7% | +336.7% | -6.5% | -0.2% | -87.2% | -0.6% | +387.9% | -1.1% | +46.4% | |
| – | -5.5% | -20.8% | +67.8% | -21.2% | +85.0% | +7.7% | -0.8% | +3.1% | -5.3% | -22.2% | -14.8% | |
| – | -12.6% | -24.6% | +33.7% | -37.8% | +67.4% | -30.2% | -5.5% | +12.4% | +134.4% | -8.2% | -24.0% | |
| – | -95.7% | – | – | – | – | – | – | – | – | -25.0% | -97.6% | |
| – | +7.2% | +8.0% | +3.7% | +175.0% | -57.1% | -58.6% | -7.3% | +7.9% | +36.6% | +7.1% | +18.3% | |
| – | – | – | – | +0.0% | +140.0% | +33.3% | +0.0% | +0.0% | -62.5% | – | – | |
| – | +26.4% | +16.4% | +12.9% | +32.7% | -0.3% | +22.1% | +16.6% | +21.2% | +24.8% | +7.7% | +10.1% | |
| – | +61.0% | +41.5% | +16.9% | +20.7% | -3.2% | +15.5% | +12.4% | +16.9% | +19.5% | +19.8% | +18.5% | |
| – | -5.4% | -8.6% | -4.1% | -2.0% | -0.5% | +1.8% | +6.1% | +2.5% | +2.5% | -2.4% | -1.2% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.